ClinicalTrials.gg
CompletedNCT05683496TEDUpdated Jul 1, 2025

Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

A Phase 1/2 interventional study of lonigutamab and Placebo in Thyroid Eye Disease, sponsored by ACELYRIN Inc.. Completed at 11 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by ACELYRIN Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Graves Ophthalmopathy with a site in United States — 12 open to participants now, 18 under way, 8 of them phase 3. Graves Ophthalmopathy · United States.

Enrollment
35th of 47
31 · median 84
Started
2023
with 6 others
Phase 1/2
4 of 53
1 open now
Registered
22nd of 53
by date
Lead sponsor
1 of 53
ACELYRIN Inc.

Among the 53 studies in Graves Ophthalmopathy with a site in United States, this one is the 35th largest by enrollment of the 47 interventional ones that give a count, is one of 7 that started in 2023, is one of 4 in phase 1/2, and was the 22nd registered.

Graves Ophthalmopathy

200 studies on the registry are indexed under Graves Ophthalmopathy; 59 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

12 of the 53 studies in Graves Ophthalmopathy with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 17 (44%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Graves Ophthalmopathy with a site in United States, or all of them as a file.
02

Study summary

Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.

03

Conditions studied

  • Thyroid Eye Disease

Browse trials for

Keywords

  • TED
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female, ≥18 and ≤75 years of age.
  • Proptosis defined in the study eye as ≥3 mm above normal.
  • Clinical Activity Score (CAS) ≥4 (using a 7-item scale) for the most severely affected eye
  • Onset of active TED symptoms prior to baseline
  • Must agree to use highly effective as specified in the protocol

Key Exclusion Criteria:

  • Pathology related to inflammatory bowel disease or irritable bowel syndrome.
  • pathology related to hearing or history of hearing impairment
  • Optic neuropathy
  • Corneal decompensation unresponsive to medical management.
  • Previous orbital irradiation (for any cause) or any previous surgical treatment for TED.
  • Subjects with diabetes or >6.0% at screening
  • Any use (intravenous [IV] or oral) with a cumulative dose equivalent to >3 g of methylprednisolone for the treatment of TED within the last year.
  • Previous steroid use (IV or oral) specifically for the treatment of TED not to exceed 1 g total dose in the 8 weeks prior to Screening.
  • Previous use of teprotumumab or any other IGF-1 receptor (IGF-1R) inhibitor.
  • Any previous treatment with a biologic drug for the treatment of TED (eg, rituximab and tocilizumab)
  • Any other agent within 1 month of screening.
  • Cohort 4 only: Prior history of craniofacial surgery or medical conditions that could alter orbital or facial features.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Single SC injection of dose 1 of lonigutamab or placebo at Day 1 and Day 21

    Drug: lonigutamab · Drug: Placebo

  • Experimental
    Cohort 2

    multiple doses of dose 2 of lonigutamab administered SC injection weekly

    Drug: lonigutamab

  • Experimental
    Cohort 3

    multiple doses of lonigutamab dose 3 administered SC injection every 4 weeks.

    Drug: lonigutamab

  • Experimental
    Cohort 4

    multiple doses of lonigutamab dose 4 administered SC injection every 4 or 3 weeks.

    Drug: lonigutamab

Interventions

  • Druglonigutamab

    subcutaneous injection

  • DrugPlacebo

    subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Incidence and characterization of nonserious treatment emergent adverse events (TEAEs)

    Safety and Tolerability

    Time frame: Day 1 to Day 169

  2. Incidence and characterization of serious treatment emergent adverse events (TEAEs)

    Safety and Tolerability

    Time frame: Day 1 to Day 169

Secondary outcomes

  1. PK profile of lonigutamab

    minimum observed concentration (Cmin)

    Time frame: Day 1 to Day 169

  2. PK profile of lonigutamab

    Maximum observed concentration (Cmax)

    Time frame: Day 1 to Day 169

07

Study locations

11 sites
  • Clinical Research Site
    Jacksonville, Florida 32216, United States
  • Clinical Research Site
    Atlanta, Georgia 30328, United States
  • Clinical Research Site
    Ann Arbor, Michigan 48108, United States
  • Clinical Research Site
    East Setauket, New York 11733, United States
  • Clinical Research Site
    New York, New York 10028, United States
  • Clinical Research Site
    Morgantown, West Virginia 26505, United States
  • Clinical Research Site
    Sydney, New South Wales 2109, Australia
  • Clinical Research Site
    Woolloongabba, Queensland 4102, Australia
  • Clinical Research Site
    Adelaide, South Australia 5000, Australia
  • Clinical Research Site
    East Melbourne, Victoria 3002, Australia
  • Clinical Research Site
    Nedlands, Western Australia 6009, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in May 2025, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2022
First posted
Jan 13, 2023
StartActual
Feb 14, 2023
Primary completionActual
May 26, 2025
CompletionActual
May 26, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05683496
Lead sponsor
ACELYRIN Inc.
Responsible party
Sponsor
First posted
Jan 13, 2023
Start date
Feb 14, 2023
Primary completion
May 26, 2025
Completion
May 26, 2025
Last update
Jul 1, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion